Pathogenic Variants in PIGG Cause Intellectual Disability with Seizures and Hypotonia  by Makrythanasis, Periklis et al.
ARTICLE
Pathogenic Variants in PIGG Cause
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Glycosylphosphatidylinositol (GPI) is a glycolipid that anchors>150 various proteins to the cell surface. At least 27 genes are involved in
biosynthesis and transport of GPI-anchored proteins (GPI-APs). To date, mutations in 13 of these genes are known to cause inherited GPI
deficiencies (IGDs), and all are inherited as recessive traits. IGDsmainly manifest as intellectual disability, epilepsy, coarse facial features,
andmultiple organ anomalies. These symptoms are caused by the decreased surface expression of GPI-APs or by structural abnormalities
of GPI. Here, we present five affected individuals (from two consanguineous families from Egypt and Pakistan and one non-consanguin-
eous family from Japan) who show intellectual disability, hypotonia, and early-onset seizures.We identified pathogenic variants in PIGG,
a gene in the GPI pathway. In the consanguineous families, homozygous variants c.928C>T (p.Gln310*) and c.2261þ1G>Cwere found,
whereas the Japanese individual was compound heterozygous for c.2005C>T (p.Arg669Cys) and a 2.4 Mb deletion involving PIGG.
PIGG is the enzyme that modifies the second mannose with ethanolamine phosphate, which is removed soon after GPI is attached
to the protein. Physiological significance of this transientmodification has been unclear. Using B lymphoblasts from affected individuals
of the Egyptian and Japanese families, we revealed that PIGG activity was almost completely abolished; however, the GPI-APs had
normal surface levels and normal structure, indicating that the pathogenesis of PIGG deficiency is not yet fully understood. The discov-
ery of pathogenic variants in PIGG expands the spectrum of IGDs and further enhances our understanding of this etiopathogenic class of
intellectual disability.Introduction
With an estimated prevalence of approximately 1%,1 intel-
lectual disability isoneof themost commondisorders of the
human population. Different definitions are available, but
the general consensus is that the IQ should be below
70 and symptoms should appear during the development
period and affect all aspects of adaptive functioning
(conceptual, social, and practical).2,3 Intellectual disability
has several etiologies, and its genetic causes, including chro-
mosomal aneuploidies, copy-number variants (CNVs), and
monogenic disorders, are estimated to account for 25%–
50% of the total cases. The identification of genic variants
responsible for monogenic disorders has been revolu-
tionized since the widespread use of high-throughput
sequencing.4,5
Glycosylphosphatidylinositol (GPI) is a glycolipid that
anchors more than 150 proteins to the cell surface. GPI-
anchored proteins (GPI-APs) have various important roles
on the cell surface. At least 27 genes are involved in the
biosynthesis and transport of GPI-APs. Among them, those
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The Am(phosphatidylinositol glycan) genes, and those that are
involved in the modification of GPI after attachment to
proteins are called PGAP (post-GPI attachment to proteins)
genes.6
The first reported inherited GPI deficiency (IGD) was
PIGM (MIM: 610273) deficiency in individuals suffering
from portal thrombosis and seizures without intellectual
disability.7,8 The mutation was located in the promoter,
which disrupted the binding of transcriptional factor SP1
and decreased promoter acetylation, leading to decreased
expression of PIGM. Many more IGDs have been recently
found via whole-exome sequencing (WES). Most IGDs
caused by the defect in PIG genes, such as PIGA
(MIM: 311770),9–13 PIGQ (MIM: 605754),14 PIGY
(MIM: 610662),15 PIGL (MIM: 605947),16,17 PIGW (MIM:
610275),18 PIGV (MIM: 610274),19,20 PIGN (MIM:
606097),21–23 PIGO (MIM: 614730),24–26 and PIGT (MIM:
610272),27,28 are partial deficiencies given that complete
loss of function of these genes causes embryonic death.29
These IGDs show decreased amounts of various GPI-APs
and can be diagnosed by flow cytometry of granulo-
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disability, epilepsy, and coarse facial features. Although the
symptoms are very broad, other characteristic features
sometimes seen include a tented upper lip, brachytelepha-
langy with hypoplastic nails, hearing loss, and multiple
organ anomalies, such as an aganglionic megacolon and
kidney or anorectal anomalies.9–27
In PGAP1 (MIM: 611655) deficiency, surface levels of
GPI-APs are not affected. Similarly, GPI-AP levels in
PGAP3 (MIM: 611801) deficiency are variable and some-
times not affected. Therefore, abnormalities in these defi-
ciencies are most likely caused by the abnormal structures
of proteins’ membrane anchors. In these cases, the individ-
uals with complete deficiencies are alive and show only
severe intellectual disability, often with seizures and hypo-
tonia.30–32 Hyperphosphatasia is a useful marker for diag-
nosing defects in PIG genes involved in later steps of the
GPI-biosynthesis pathway, such as PIGV and PIGO, because
the protein part of alkaline phosphatase (ALP) is secreted
from the endoplasmic reticulum (ER) without attachment
to the GPI anchor. PGAP2 (MIM: 615817) and PGAP3 defi-
ciencies also show hyperphosphatasia32–34 because once
ALP is anchored to the membrane by GPI, it is released
from the cell surface. Thus, the symptoms vary in severity
depending upon the degree of the defect and/or position
in the pathway of the affected gene.
Here, we report five individuals (from three different
families) who suffer from intellectual disability and hypo-
tonia and carry loss-of-function variants in PIGG (phos-
phatidylinositol glycan anchor biosynthesis, class G).
PIGG is the enzyme that attaches ethanolamine phosphate
(EtNP) to the second mannose. Different from other PIG
genes, PIGG is not essential for GPI-AP biosynthesis. GPI-
APs in PIGG-deficient cells are present at normal levels
and have normal structures because EtNP on the second
mannose is removed by PGAP5 (HGNC-approved gene
symbol: MPPE1 [MIM: 11900]) in the ER physiologi-
cally.35 However, the discovery of individuals with PIGG
deficiency reveals that this step is also important for
neurological development.Subjects and Methods
Clinical Reports of Affected Individuals
This study was approved by the institutional review boards of
Osaka University (Japan), Yokohama City University School
of Medicine (Japan), Yamagata University (Japan), University of
Geneva (Switzerland), and National Research Centre (Egypt).
Ethical approval for molecular genetics research studies and data
use was obtained from the South Yorkshire Research Ethics Com-
mittee (reference no. 11/H1310/1; UK). Informed consent was
obtained from all examined persons or their guardians.
The affected individuals belong to three different families iden-
tified in three different studies. An overview of the clinical find-
ings, along with a comparison to the phenotype of other IGDs,
can be found in Table 1, and detailed clinical descriptions can be
found in the Supplemental Note. In brief, the individuals in family
EG (V:1 [EG01] and V:5 [EG02], now aged 24 and 14 years, respec-616 The American Journal of Human Genetics 98, 615–626, April 7, 2tively) are the offspring of a consanguineous marriage between
first cousins originating from Egypt. They presented with hypoto-
nia, seizures (at 4 months of age) that were not easily controlled
by drug therapy, and profound uniform developmental delay or
intellectual disability. The individual in family JP (V:6 [JP01])
was born to non-consanguineous healthy Japanese parents
(Figure 1). Seizures were first noted at the age of 10 months. She
developed severe psychomotor developmental delay with no
speech development, autistic features, and growth retardation
with a poor appetite. The individuals in family PK (V:9 [PK01]
and V:10 [PK02], presently 12 and 10 years old, respectively), are
offspring of a mating between first cousins of Pakistani origin
(Figure 1). They had severe delay in their motor development.
The first individual has had a single episode of seizures, whereas
the second individual has not had any epileptic episodes.
All affected individuals from the three families had either no
dysmorphic features (families JP and PK) or no common features
(family EG), and the common symptoms were hypotonia,
severe developmental delay, and seizures. Electroencephalography
(EEG) of the individuals in family EG showed that seizures were
temporal and had secondary generalization, whereas EEG of the
individual in family JP showed that seizure waves were in the right
parietotemporal regions and propagated to the right hemisphere
(Figure 2B, lower panel). BrainMRI showed a thin corpus callosum
and asymmetry of the lateral ventricles in both individuals in fam-
ily EG (Figure 2A), normal findings in the individual in family JP
(Figure 2B, right upper panel), and cerebellar hypoplasia and
mild cerebral atrophy in both individuals in family PK (Figure 2C).Variant Identification
Egyptian Family
Variant identification was performed as previously described.36 In
brief, all familymembers for whomDNAwas available (noted hori-
zontal bars, Figure 1)were genotypedwith theHumanOmniExpress
Bead Chip (Illumina), and the genotypes were used for identifying
runs of homozygosity in each individual. Simultaneously in the
eldest individual, the exome was captured with SureSelect Human
All Exon V3 (Agilent), and the produced libraries were sequenced
in an Illumina HiSeq 2000. Variant identification was performed
with publicly available algorithms and then with genotyping data,
and the variants identified through exome sequencing were com-
bined with CATCH (Consanguinity Analysis through Common
Homozygosity)37 for the creation of a final list of candidate variants.
All identified variants were confirmed by Sanger sequencing, and
family segregation was confirmed.
Japanese Family
Genomic DNA was captured with the SureSelect Human All Exon
V5 (Agilent Technologies) and sequenced on an Illumina HiSeq
2000 with 101 bp paired-end reads. Exome-data processing,
variant calling, and variant annotation were performed as
described previously.38 Copy-number analysis using WES data
was performed with eXome Hidden Markov Model v.1.0
(XHMM) as previously described.39,40 Microdeletion involving
PIGG was validated by quantitative real-time PCR (qPCR) on a
Rotor-Gene Q thermal-cycling system (QIAGEN) with DNA from
the affected individual and parents. PCR was performed in a vol-
ume of 15 ml containing 10 ng of genomic DNA, 13 Rotor-Gene
SYBR Green PCR Master Mix (QIAGEN), and 1.0 mM of each
primer. qPCR was carried out with the relative standard-curve
method with four standard samples (30, 10, 3.33, and 1.11 ng
DNA). Two primer sets for exons 7 and 12 of PIGG and two016
reference primer sets for an area on chromosomes 9 and 15 were
used. Relative copy numbers of test regions were independently
calculated in comparison with those of the two reference regions
and were averaged. Primer information is available on request.
Pakistani Family
Target capture was performed with the Agilent SureSelect All Exon
V4 Exome Enrichment Kit according to the manufacturer’s stan-
dard protocols. Sequencing of 150 bp paired-end reads was per-
formed with an Illumina MiSeq. Reads were aligned to GRCh37
with Novoalign (Novocraft Technologies) and processed with the
Genome Analysis Toolkit (GATK) and Picard (see Web Resources)
for realignment of short insertions and deletions (indels) and
removal of duplicate reads.Depthof coverageof the consensus cod-
ing sequence (CCDS) was assessed with the GATK, which showed
that>94%ofCCDSbaseswere covered by at least five good-quality
reads (minimum Phred-like base quality of 17 andminimummap-
ping quality of 20). Single-nucleotide variants (SNVs) and indels
were called with the UnifiedGenotyper feature of the GATK.41,42
Generation of LCLs, PI-PLC Treatment, and Analysis
by Fluorescence-Activated Cell Sorting
Lymphoblastoid cell lines (LCLs) were generated from the affected
individuals’ B-lymphocytes and cultured in RPMI 1640-R2405
(Sigma-Aldrich) supplemented with 10% fetal calf serum. The
LCLs were transfected with an empty pMEoriP vector or
pMEoriP-humanPIGG-GST. Cells were suspended in 0.8 ml of
Opti-MEM and electroporated with 20 mg each of the plasmids at
260 V and 960 mF with a Gene Pulser (Bio-Rad). Permanently
transfected cells were obtained by selection with 0.5 mg/ml puro-
mycin. Those cells were treated with or without 10 units/ml of
phosphatidylinositol-specific phospholipase C (PI-PLC; Molecular
Probe) for 1.5 hr at 37C. Surface expression of GPI-APs was deter-
mined by cell staining with phycoerythrin (PE)-conjugated mouse
anti-human CD59 (5H8).
Functional Assay of PIGG: Determining PIGG-
Dependent Generation of Mature GPI by Analyzing
GPI Mannolipids
Affected individuals’ LCLs were labeled with 14C-mannose. A total
of 106 cells were incubated for 1 hr in a medium containing
100 mg/ml glucose and 10 mg/ml tunicamycin (Sigma) and
then incubated in the same medium containing 0.5 mCi/ml
14C-mannose (American Radiolabeled Chemicals) for 1 hr. Lipids
were extracted and partitioned into n-buthanol. Glycolipids were
separated on Kiesel gel 60 (Merck) and detected by a BAS-1500
image analyzer (Fujifilm). H8 indicated a complete GPI anchor,
and H7 indicated a GPI-anchor intermediate without EtNP at
the second mannose. A fourth mannose was added to the third
mannose in H7 and H8 for the generation of H70 and H80, respec-
tively. Each affected individual’s cell was permanently transfected
with PIGG cDNA or an empty vector. The positive control was
lipid extracts from radiolabeled PIGK-deficient K562 cells in which
the complete GPI anchor (H8) had accumulated.
Western Blotting
Lipofectamine 2000 (Invitrogen) was used for transiently trans-
fecting HEK293 cells with SRa-promoter-driven cDNA encoding
wild-type or mutant PIGG tagged with hemagglutinin (HA) at
the N terminus (pME HA-hPIGG). Two days later, lysates were
applied to SDS-PAGE, and HA-tagged PIGG was assessed by west-
ern blotting using anti-HA antibody.The AmAnalysis by Fluorescence-Activated Cell Sorting
Surface levels of GPI-APs were determined by cell staining with
Alexa 488-conjugated inactivated aerolysin (fluorescently-labeled
inactive toxin aerolysin; Protox Biotech) and the following appro-
priate antibodies: PE-conjugated mouse anti-decay accelerating
factor (DAF; IA10), anti-CD16 (3G8), anti-CD24 (ML5), anti-
CD59 (5H8), and anti-CD48 (BJ40) antibodies (Biolegend). Cells
were analyzed by flow cytometry (MACSQuant Analyzer 10, Milte-
nyi Biotec) with Flowjo software (v.9.5.3, Tommy Digital).
Generation of PIGG-Knockout HEK293 Cells
PIGG-knockout cells were generated from HEK293 cells via the
CRISPR/Cas9 system. The human-codon-optimized Streptococcus
pyogenes Cas9 and chimeric guide RNA expression plasmid
pX330 were obtained from Addgene. The seed sequences for the
SpCas9 target sites in PIGG exons 1 and 2 were selected, and a
pair of annealed oligonucleotides designed according to these se-
quences were cloned into the BbsI sites of pX330. Lipofectamine
2000 was used for transfecting HEK293 cells with two kinds of
pX330 containing the target sites. The candidate PIGG-knockout
clones were obtained by limiting dilution and further selected
by PCR and direct sequencing.Results
Exome Sequencing and Genotyping of Family EG
After exome sequencing, 42,995,036 reads were on target
in that they covered 89.12% of the coding exons as defined
in RefSeq at 83. Of the 20,119 high-quality exonic variants
identified, 10,187 were synonymous and 9,021 were
missense. After genotyping, we verified the correct family
structure and identified that the parents share 17.9% of
their genomes.
These data were combined through CATCH,37 and after
analysis of the results, three variants remained for further
evaluation (Table S1) in genes PIGG (c.928C>T
[p.Gln310*] [GenBank: NM_001127178.2]), COQ5 (MIM:
616359; c.319G>A [p.Gly107Arg] [GenBank: NM_
032314.3]), and RGS12 (MIM: 602512; c.188A>T
[p.Gln63Leu] [GenBank: NM_002926.3]). All variants
were confirmed by Sanger sequencing, and family segrega-
tion confirmed that the affected individuals, as well as the
unaffected siblings, are heterozygous for the variants
(Figure 3A). Variants in PIGG and COQ5 are not present
in publically available databases, whereas the variant in
RGS12has a cumulative frequency of 4.95e5 in the Exome
Aggregation Consortium (ExAC) Browser.43 The variant in
PIGG is nonsense, whereas the other two are missense.
PIGG was considered the most prominent candidate
because the variant identified causes a clear loss of function.
A recent inquiry of the ExAC Browser verified that no
homozygous loss-of-function variants have been reported
and that the most common loss-of-function variant,
c.1515G>A (p.Trp505*) (GenBank: NM_001127178.2),
has a minor allele frequency (MAF) of 0.0012 in the
European population. This translates to a frequency of
less than 1 in 600,000 individuals, compatible with a rare
autosomal-recessive disorder.erican Journal of Human Genetics 98, 615–626, April 7, 2016 617
Table 1. An Overview of the Affected Individuals’ Symptoms and a Comparison with the Different Aspects of the Already Identified IGDs
Clinical Syndrome
MCAHS2
Ohtahara
Syndrome HPMRS6
CHIME
Syndrome HPMRS5
Inherited GPI
Deficiency HPMRS1
MIM no. 300868 3008350 616809 280000 616025 610293 239300
Associated gene
(MIM no.)
PIGA (311770) PIGQ (605754) PIGY (610662) PIGL (605947) PIGW (610275) PIGM (610273) PIGV (610274)
GPI-biosynthesis
stepa
GPI biosynthesis (ER cytoplasmic side) GPI biosynthesis (ER lumen side)
step 1 step 1 step 1 step 2 step 4 step 6 step 7
No. of families
(affected
individuals)
9 (13) 1 (1) 2 (4) 6 (7) 1 (1) 2 (3) 14 (20)
Mode of inheritance
(locus)
X-linked (Xp22.2) AR (16p13.3) AR (4q22.1) AR (17p11.2) AR (17q12) AR (1q23.2) AR (1p36.11)
Clinical Features
DD or ID þ þ þ/ þ þ þ þ
Seizures þ (<1 year) þ (<1 year) þ/ þ (<1 year) þ (<1 year) þ þ
Hypotonia þ þ þ/ þ þ  þ
Head
circumference
ND ND  or microcephaly ND ND ND ND
Facial
dysmorphism
þ/ NA þ þ þ  þ
Hearing
impairment
þ NA  þ   þ/
Joint
contractures
þ þ þ/ ND ND ND ND
Skeletal
anomalies
ND ND short fingers
and small feet,
proximal limb
shortening,
hip dysplasia
ND ND ND hypoplastic
terminal
phalanges
Skin
anomalies
þ/   þ/   
Congenital
heart defects
þ/   þ/   þ/
Vesicoureteral
reflex or
anomalies in
urinary tract
þ/  þ/ þ/   þ/
Anorectal
anomalies
      þ/
CNS abnormalities
in MRI
þ/ þ þ/ þ/ þ  þ
Increased serum
alkaline phosphatase
þ/ (mild)  þ/ (mild) þ/ þ  þ
Decreased GPI-AP þ NA þ þ þ þ þ
Abbreviations are as follows: þ, present; , absent; þ/, variable; AR, autosomal recessive; MCAHS, multiple congenital anomalies-hypotonia-seizures
syndrome; CHIME, colobomas, congenital heart disease, ichthyosiform dermatosis, mental retardation, and ear anomalies; HPMRS, hyperphosphatasia with
mental retardation syndrome; MRT42, mental retardation, autosomal recessive 42; DD, development delay; ID, intellectual disability; NA, not applicable; and
ND, not determined.
aBased on the review by Kinoshita.6
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MCAHS1 HPMRS2 IGD Identified in This Study MCAHS3 MRT42 HPMRS4 HPMRS3
614080 614749 NA 615398 611655 615716 614207
PIGN
(606097)
PIGO
(614730)
PIGG (not assigned) PIGT (610272) PGAP1
(611655)
PGAP3
(611801)
PGAP2
(615187)
GPI transamidase
component (ER)
removal of
inositol-linked
acyl chain (ER)
lipid remodeling in Golgi
step 8 step 10 step 11 step 12 step 13 step 16 step 17
9 (17) 4 (6) 1 (EG01 and
EG002)
1 (JP01) 1 (PK01 and
PK02)
3 (7) 5 (7) 4 (6) 4 (9)
AR
(18q21.33)
AR (9p13.3) AR (4p16.3) AR (4p16.3) AR (4p16.3) AR (20q13.12) AR (2q33.1) AR (17q12) AR (11p15.4)
þ þ/ þ þ þ þ þ þ þ
þ (<1 year) þ þ (4 months) þ (10 months) þ/ þ (<1 year) þ/ þ/ þ/
þ þ þ þ þ þ þ þ þ
 or
microcephaly
 or
microcephaly
ND ND ND  or
microcephaly
 or
microcephaly
 or
microcephaly
ND
þ þ þ   þ  þ þ/
 þ/    þ/   þ/
ND ND hyperlaxity   ND ND ND ND
ND hypoplastic
terminal
phalanges
   osteopenia, scoliosis
delayed bone age,
short arms
ND ND ND
        
þ/ þ/    þ/   þ/
þ/     þ/   
þ/ þ/    þ/   þ/
þ/ þ/ thin corpus
callosum
 cerebellar
hypoplasia,
cerebral
atrophy
þ þ/ þ/ þ/
 þ   NA  (hypophosphatasia)  þ þ
þ þ    þ  þ/ þ
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Figure 1. Family Pedigrees
The affected individuals are noted as EG01,
EG02, JP01, PK01, and PK02. The family
members for whom DNA was available
are noted with a horizontal bar above their
respective symbols. Affected individuals
are homozygous or compound heterozy-
gous for the causative variants, and family
members are verified carriers. In family JP,
the second variant is a de novo CNV that
encompasses PIGG.Exome Sequencing of Family JP
Wehave been conductingWES analysis of inherited intrac-
table disorders, including infantile epilepsy, as a Japan na-
tional project since 2011. Searching WES data of 437 indi-
viduals with infantile epilepsy, we identified a PIGG variant
(c.2005C>T [p.Arg669Cys] [GenBank: NM_001127178.2])
in the affected individual in family JP, and it seemed homo-
zygous (no reads for the reference allele and 57 reads for
the variant allele). The c.2005C>T variant was found in 4
of 575 in-house control exomes and has a MAF of 0.06%
in the East Asian population according to the ExAC
Browser. Web-based prediction tools suggested that the
c.2005C>T variant is pathogenic (Table S1). Sanger
sequencing using DNA of the affected individual and her
parents revealed that the father has the heterozygous
c.2005C>T variant but that the mother does not
(Figure 3B). Because the affected individual showed only
the variant T allele, one or two alleles with the
c.2005C>T variant from her father should exist, and the
maternal allele might be missing in the affected individual.
In fact, a microdeletion involving PIGG (chr4: 60,226–
2,452,836) was indicated by XHMM analysis using WES
data (Figure 3C). qPCR analysis confirmed the heterozy-
gous PIGG deletion in the affected individual, but not in
her mother, suggesting that the microdeletion should
have occurred de novo on the maternal chromosome
(Figure 3D).
Exome Sequencing and Genotyping of Family PK
Custom Perl scripts were used for removing variants pre-
sent in dbSNP132 or with a MAF R 0.1% and for anno-
tating functional consequences. We called variants in the
autozygous region only with a minimum Phred-like geno-
type quality of 30 and selected for indels within coding620 The American Journal of Human Genetics 98, 615–626, April 7, 2016regions, non-synonymous SNVs, and
splice-site variants. Variants present
in the 1000 Genomes dataset
(November 2011), the National Heart,
Lung, and Blood Institute (NHLBI)
Exome Sequencing Project (ESP)
Exome Variant Server, and another
2500 ethnically matched in-house
exomes were also removed. This
left a single variant, c.2261þ1G>C
(GenBank: NM_001127178.1), whichwas confirmed as present in the affected individuals and
segregated with the phenotype in the family according to
Sanger sequencing (Figure 3E).
Functional Analysis of the PIGG Mutants
PIGG is an EtNP transferase that mediates conversion of
GPI precursor H7 to mature GPI precursor H8 (Figure S2).
H8 is normally attached to proteins for the generation
of GPI-APs. H7 is also competent for protein attachment,
and in the absence of H8, H7 is alternatively used as an
anchor. A fourth mannose can be added to H7 and H8
for the generation of H70 and H80, respectively. Culturing
cells with radioactive mannose and analyzing themetabol-
ically radiolabeled GPI precursors by thin-layer chromatog-
raphy and phosphoimaging can be used for determining
generation of H7, H70, H8, and H80 in cells. To determine
whether PIGGmutations found in families EG and JP affect
functional activity of PIGG, we cultured individuals’ LCLs
in a medium containing 14C-mannose and analyzed the
metabolically radiolabeled GPI precursors (Figure 4A). H7
and H70 were accumulated in LCLs from all three affected
individuals (black arrowheads [H7] and double asterisks
[H70] in lanes 4, 6, and 9 for individuals EG01, EG02,
and JP01, respectively), suggesting that mutant PIGG
could not add EtNP to H7 to generate H8. Such accumula-
tion of H7 and H70 was not seen in LCLs from a healthy
individual or the father of affected individuals EG01 and
EG02 (lanes 1 and 2). Importantly, these accumulation
profiles of affected individuals’ LCLs disappeared after
transfection of normal PIGG cDNA (lanes 3, 5, and 8). H8
and H80 (white arrowheads [H8] and single asterisk [H80]
in lanes 1 and 7, respectively; positive control) were not
or were only weakly seen in affected individuals’ LCLs,
whereas they were restored by transfection of PIGG
Figure 2. MRI and EEG of the Affected Individuals
(A) MRI of individual EG02 when she was 2.5 years old. (Left panel) Mid-sagittal T1-weighted MRI shows the thin corpus callosum.
(Right panel) Axial plane in T1- and T2-weighted MRI shows asymmetry of the lateral ventricles.
(B) MRI and EEG of individual JP01. (Upper left panel) Interictal EEG during sleep at the age of 3 years shows focal spikes on the right
posterior area (C4-P4-O2-T6, arrows). (Lower panel) Ictal EEG at 14 months shows that low-amplitude fast waves arose from right cen-
trotemporal lesions (C4-T4, arrowheads) and then propagated to the entire right hemisphere. According to the ictal discharge, the in-
dividual developed eye deviation and head turning to the right after clonic seizures of the left upper extremity. (Upper right panel) T2-
weighted brain MRI at the level of basal ganglia shows normal appearance at 11 months.
(C) MRI of individual PK01. (Left panel) Mid-sagittal T1-weighted MRI shows cerebellar hypoplasia. (Right panel) Axial plane in T2-
weighted MRI shows mild cerebral atrophy.cDNA (compare lanes 3 and 4, lanes 5 and 6, and lanes 8
and 9). These results indicate that the PIGG mutations
in both families disrupt PIGG functional activity almost
completely (Figure 4A).
It was predicted that the mutation in family EG would
cause the generation of truncated PIGG because of the
p.Gln310* change, whereas the p.Arg669Cys variant in
family JP would not affect the apparent molecular size
of PIGG. For analysis of mutant PIGG proteins, amounts
of N-terminally HA-tagged wild-type, p.Gln310*, and
p.Arg669Cys PIGG were detected in HEK293 cells by
anti-HA antibody after western blotting. p.Gln310* PIGG
was present at a high level as a truncated protein of
48 kDa, an expected size (Figure 4B). p.Arg669Cys PIGG
was present at a level comparable to that of a 100 kDa
wild-type PIGG, indicating that the Arg-to-Cys substitu-
tion disrupts PIGG functional activity without affecting
its stability.
To investigate whether PIGG deficiency affects surface
levels of GPI-APs, we used flow cytometry to analyze the
granulocytes (Figure 5A) and LCLs from individuals EG01
and EG02 (Figure 5B, upper panels) and the LCLs fromThe AmJP01 (Figure 4B, lower panels). Surface levels of various
GPI-APs were similar on the cells of both affected individ-
uals and healthy individuals, suggesting that they are not
affected by loss-of-function mutations in PIGG. Making
PIGG-knockout HEK293 cells with the CRISPR/Cas9 sys-
tem further confirmed that complete loss of PIGG does
not affect cell-surface levels of GPI-APs (Figure 5C).
Recently, individuals with PGAP1 mutations were re-
ported.30 They had intellectual disability, developmental
delay, encephalopathy, cerebral visual impairment, or he-
reditary spastic paraplegia. The complete-loss-of-function
mutations in PGAP1 did not affect the cell-surface levels
of GPI-APs but caused structural abnormality of lipid moi-
ety in GPI. Because PGAP1 removes the inositol-linked acyl
chain of GPI-APs at the next step after protein attachment
to the GPI anchor in the ER (Figure S2), it is possible that
PGAP1 might not act on GPI-APs lacking EtNP on the sec-
ond mannose in cells with mutant PIGG. Additionally,
given that PIGG mutations caused neurological pheno-
types without causing reduction in the steady-state cell-
surface levels of GPI-APs (similarly to PGAP1 deficiencies),
we investigated the possibility of an abnormal GPIerican Journal of Human Genetics 98, 615–626, April 7, 2016 621
Figure 3. Identified Variants
(A) Sequencing chromatograms of the identified variant in family EG. The parents and unaffected siblings are heterozygous, whereas the
affected individuals are homozygous for the c.928C>T mutation (noted by the black arrow).
(B) Sequencing chromatograms of the identified variant in family JP. The father has the heterozygous c.2005C>T variant, but themother
does not (noted by the black arrow).
(C) XHMM analysis using WES data of individual JP01. A microdeletion involving PIGG (chr4: 60,226–2,452,836) is indicated.
(D) qPCR analysis of exons 7 and 12 of the PIGG genome from individual JP01 and her parents shows a heterozygous PIGG deletion in
the affected individual, but not in her mother, suggesting that the deletion occurred de novo on the maternal chromosome.
(E) Sequencing chromatograms of the identified variant in family PK are noted by the blue transparent boxes. The parents are
heterozygous, and the affected individuals are homozygous for the c.2261þ1G>C mutation.structure. LCLs from the individuals were treated with PI-
PLC, a bacterial enzyme that cleaves GPI between phos-
phate and glycerol and releases proteins. PI-PLC does not
cleave GPI if the inositol residue is acylated. CD59 levels
of PIGG-defective cells and PIGG-transfected PIGG-defec-
tive cells were similarly reduced by PI-PLC treatment, indi-
cating that elimination of the acyl chain from the inositol
normally occurs in LCLs from three affected individuals
(Figure S1). Therefore, the structure of GPI in GPI-APs on
cells with mutant PIGG would be normal.Discussion
Various symptoms of IGDs are caused by reduced surface
levels of GPI-APs or by abnormal GPI-AP structure. Here,
we report PIGG deficiency, one IGD in which cells express
normal surface levels of GPI-APs with a normal structure.
Nevertheless, individuals from families EG and JP suffer
from intellectual disability, hypotonia, and seizures, and
individuals from family PK show severe intellectual
disability accompanied by ataxia. In individuals from fam-
ily EG, hypotonia has been remarkable since birth and re-622 The American Journal of Human Genetics 98, 615–626, April 7, 2mains a characteristic symptom of the disorder. Later, it
was seen as hyporeflexia and a delay in achieving walking.
The affected individual in family JP showed more severe
developmental delay, and she could not walk or speak.
In both affected individuals from families EG and JP,
seizures appeared early in life, and developmental delay
was also documented early in life and evolved to uniform
intellectual disability. The affected individuals described
here did not present with coarse faces, dysmorphic fea-
tures, or other accompanying symptoms frequently seen
in IGDs. Intellectual disability with seizures and severe
hypotonia appear to be common characteristics of PIGG
deficiency.
Through in vitro testing of affected individuals’ LCLs, we
showed that the identified variants completely abolished
the function of PIGG, whereas the surface level of GPI-AP
was normal. We obtained a similar result with PIGG-
knockout HEK293 cells. Apparently H7 was used as an
alternative GPI anchor. The EtNP transferred by PIGG to
the second mannose is a transient side branch that is
removed by phosphodiesterase PGAP5 in the second step
after GPI is attached to the protein and that is not present
in mature GPI-APs35 (Figure S2). Therefore, the lack of this016
Figure 4. Functional Assays
(A) Analysis of mannolipids accumulated in
LCLs from the affected individuals. Lanes
are as follows: 1, LCLs from a normal indi-
vidual; 2, LCLs from the father of individ-
uals EG01 and EG02 (IV:3); 3, LCLs (trans-
fected with PIGG cDNA) from individual
EG01; 4, LCLs (transfected with an empty
vector) from individual EG01; 5, LCLs
(transfectedwith PIGG cDNA) from individ-
ual EG02; 6, LCLs (transfected with an
empty vector) from individual EG02; 7,
K562 PIGK-deficient cells; 8, LCLs (trans-
fected with PIGG cDNA) from individual
JP01; and 9, LCLs (transfected with an
empty vector) from individual JP01. White
arrowheads represent H8, a complete GPI
intermediate, and black arrowheads repre-
sentH7,aGPI intermediatewithout ethano-
laminephosphate at the second mannose.
Asterisks indicate H70 (*) and H80 (**), H7
and H8, respectively, with the fourth
mannose.47
(B) Amounts of each mutant PIGG. (Upper
panel) Western blot of GAPDH for loading
controls. (Lower panel) Western blot of
wild-type (*) ormutant (**)HA-taggedPIGG.transient EtNP side branch does not affect steady-state
levels of cell-surface GPI-APs on B-lymphoblastoid cells
and HEK293 cells (Figures 5B and 5C).
During GPI biosynthesis, EtNP is added to all three
mannose residues. PIGN attaches EtNP to the first
mannose at the 2-position. PIGG and PIGO attach EtNP
at the 6-positions of the second and third mannoses,
respectively, and share a common essential cofactor,
PIGF. The EtNP attached to the third mannose, so-called
‘‘bridging’’ EtNP, links GPI to proteins. PIGN, PIGO, and
PIGG constitute a family of EtNP transferases. In PIGN-
defective cells, the cell-surface GPI-APs lack the EtNP side
branch on the first mannose, and the surface levels are
also affected. PIGN deficiency is characterized by intellec-
tual disability, seizures, and multiple abnormalities. In
PIGO-defective cells, the cell-surface GPI-AP levels are
decreased because of a lack of or decrease in the ‘‘bridging’’
EtNP. PIGO deficiency causes Mabry syndrome, character-
ized by hyperphosphatasia, intellectual disability, seizures,
and brachytelephalangy. Different from these EtNP
transferase deficiencies, PIGG deficiency does not cause
decreased surface expression of GPI-APs. We investigated
the possibility of structural abnormality in GPI given that
PGAP1 does not remove the inositol-linked acyl chain in
the absence of EtNP on the second mannose and would
thus cause proteins with inositol-acylated GPI to be pre-
sent on the cell surface. However, this was proven not to
be the case (Figure S1). In PIGG-deficient cells, therefore,
GPI-APs would be normally remodeled in their fatty acid
and transported to the microdomain of the plasma mem-
brane (Figure S2). Consistent with this, PIGG-deficient in-
dividuals did not show hyperphosphatasia, which is
commonly seen in PGAP3 deficiency, the fatty-acid-re-
modeling defect.The AmAnother potential defect in PIGG-defective cells is that
transport of GPI-APs from the ER to the cell surface is de-
layed. Recognition and removal of EtNP linked to the
second mannose by PGAP5 at the ER exit site is important
for efficient packaging of GPI-APs into COPII-coated
transport vesicles and subsequent transport to the Golgi
apparatus. We investigated this possibility by using
PIGG-knockout HEK293 cells expressing doxycycline-
inducible GPI-anchored reporter protein, but we did not
detect transport delay (data not shown). Although signif-
icant delay in GPI-AP transport was not detected in
HEK293 cells, we still think that neuronal cells, in which
many important GPI-APs need to be quickly transported
to distant sites from the cell body, might require PIGG
for sufficient protein attachment of GPI or for efficient
GPI-AP transport from the ER to the plasma membrane.
Unfortunately, the available cellular systems were not
able to resolve this issue. A defect in these processes might
be relevant to neurological defects seen in individuals
with PIGG deficiency.
Although almost nothing is known about the biological
function of PIGG inmammalian cells, important functions
were reported for GP17, the yeast ortholog of PIGG. Yeast
GP17 plays an important role in cell-wall biogenesis, cell
separation, and daughter cell growth.44–46 Extensive addi-
tional experiments through the study of animal models
are required for further delineating PIGG’s function in
the human CNS.
PIGG is the 14th of the 27 known genes of the GPI-
biosynthesis pathway to be associated with human
disorders, suggesting that pathogenic variants in the other
genes participating in GPI biosynthesis remain to be
discovered in affected individuals with similar pheno-
types. The complete repertoire of genes involved inerican Journal of Human Genetics 98, 615–626, April 7, 2016 623
Figure 5. Flow Cytometric Analysis of Affected Individuals’ Blood and Cell Lines
(A) Surface level of GPI-anchored proteins on the granulocytes from individual JP01. Thick lines represent individual JP01, dotted lines
represent a healthy control individual, and gray shadows represent the isotype control.
(B) Surface level of GPI-anchored proteins on the LCLs from individuals EG01 and EG02 (upper panel) and individual JP01 (lower
panel). In the upper panels, thick and thin lines represent individuals EG01 and EG02, respectively, and dotted lines represent
their father. In the lower panels, thick lines represent affected individual JP01, and dotted and dashed lines represent healthy in-
dividuals. Gray shadows represent the isotype control.
(C) Surface level of GPI-anchored proteins on HEK293 cells. PIGG-knockout HEK293 cells were permanently transfected with PIGG
cDNA (dotted lines) or an empty vector (thick lines). Dark-gray shadows represent wild-type HEK293 cells, and light-gray shadows
represent the isotype control.GPI-biosynthesis disorders will enhance our understand-
ing of the pathophysiology of this form of ID and could
result in treatment options for these disorders.Supplemental Data
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